AHR and metabolic disease: In patients with metabolic disorders, an important gut finding is a decrease in tryptophan, which leads to a decrease in aryl hydrocarbon receptor binding and the activation of both GLP-1 and interleukin-22; this pathway ultimately promotes inflammation, insulin resistance, and hepatic steatosis (40, 41).